 Connection
Paul Bunn to Head and Neck Neoplasms
This is a "connection" page, showing publications Paul Bunn has written about Head and Neck Neoplasms.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.357 |
|
|
|
-
Raben D, Helfrich BA, Chan D, Johnson G, Bunn PA. ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non-small cell lung cancer. Semin Oncol. 2002 Feb; 29(1 Suppl 4):37-46.
Score: 0.144
-
Leonard CE, Chan DC, Chou TC, Kumar R, Bunn PA. Paclitaxel enhances in vitro radiosensitivity of squamous carcinoma cell lines of the head and neck. Cancer Res. 1996 Nov 15; 56(22):5198-204.
Score: 0.101
-
Hickinson DM, Marshall GB, Beran GJ, Varella-Garcia M, Mills EA, South MC, Cassidy AM, Acheson KL, McWalter G, McCormack RM, Bunn PA, French T, Graham A, Holloway BR, Hirsch FR, Speake G. Identification of biomarkers in human head and neck tumor cell lines that predict for in vitro sensitivity to gefitinib. Clin Transl Sci. 2009 Jun; 2(3):183-92.
Score: 0.060
-
Frederick BA, Helfrich BA, Coldren CD, Zheng D, Chan D, Bunn PA, Raben D. Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non-small cell lung carcinoma. Mol Cancer Ther. 2007 Jun; 6(6):1683-91.
Score: 0.052
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|